Five years later an MR image showed local tumor recurrence, and the patient underwent a second transsphenoidal resection followed by radiosurgery. Results of a pathological analysis revealed a tumor histologically identical to the initially resected lesion, with a Ki-67 labeling index of only approximately 1%.
In 2001 neck pain radiating to the shoulders developed in the patient. An MR image demonstrated multiple intradural extramedullary mass lesions located in the cervical and thoracic spine. A biopsy of the largest lesion at C2-4 revealed histological features similar to those of the previously resected pituitary tumor. Because the lesion had metastasized, it was diagnosed as a pituitary carcinoma. A bone scan showed lesions in the right fourth and left seventh ribs and the right proximal tibia; the pituitary mass had increased in size, causing worsening bitemporal hemianopia. Radiation therapy was applied to the spine lesions. His pain persisted and treatment with octreotide was attempted.
Temozolomide Treatment. The patient was enrolled in a Phase I study in which temozolomide was combined with pegylated interferon. The interferon was stopped after 1 month given the patient's Grade 4 fatigue (National Cancer Institute Common Toxicity Criteria, version 3.0), and the temozolomide alone was administered at 200 mg/m 2 every day for 5 days on and 23 days off, for 12 cycles. He tolerated the treatment well, and except for mild to moderate lymphocytopenia, no treatment-related complications occurred. His neck and shoulder pain disappeared, and the visual field deficits improved ( Fig. 1 ). Improvement was confirmed on MR images as well ( Fig. 2) . He is currently asymptomatic, 16 months after completing chemotherapy.
Case 2
History and Initial Examination. This 26-year-old man presented in 1995 with headaches and a progressive decrease in visual acuity. He was found to have bitemporal hemianopia with a prolactin concentration of 181 ng/ml (normal range 0-28 ng/ml). An MR image revealed a large pituitary mass, which was diagnosed as a prolactin-secreting pituitary macroadenoma.
Treatments and Pathological Analyses. Bromocriptine was administered, which led to a resolution of the patient's symptoms and a decrease in prolactin levels to 37 ng/ml. After 2 years, cabergoline was substituted for bromocriptine, but the headaches returned and visual field testing revealed worsening bitemporal hemianopia. Magnetic resonance images showed that the mass had grown. Treatment with bromocriptine was restarted, but the patient's symptoms worsened. A transsphenoidal debulking resection was performed, followed several months later by a craniotomy. Results of a pathological analysis in both instances were consistent with an invasive pituitary tumor as well as bone invasion, numerous mitoses, and an elevated MIB-1 proliferation index at 10%. The tissue stained positively for prolactin but not for growth hormone. Proton beam radiation therapy was applied to the pituitary gland. While on this treatment, the patient had intractable headaches and neck pain that were only relieved with high-dose opioid analgesic agents. Magnetic resonance images of the spine showed multiple discrete lesions involving cervical and thoracic spine vertebrae. A biopsy of a cervical spine lesion demonstrated histological characteristics identical to those of the pituitary tumor. The patient's symptoms did not respond to an escalated dose of the bromocriptine or radiation therapy to the spine. A trial of octreotide and two cycles of chemotherapy, including carboplatin, paclitaxel, and etoposide, were also ineffective. Several months later a positive MIBG scan led to treatment with 131 I-MIBG; this therapy produced some improvement in pain, although prolactin levels did not decline. Five months later, despite having received high doses of bromocriptine, his symptoms progressed and the prolactin levels increased to 694 ng/ml. A PET scan revealed progression of the spinal disease, whereas a repeated MIBG scan demonstrated no lesions.
Temozolomide Treatment. In view of the benefits observed in the patient in Case 1, we administered temozolomide at 200 mg/m 2 every day for 5 days on and 23 days off, for 10 cycles. Chemotherapy was well tolerated, but the last two cycles were withheld because of the patient's persistent fatigue. He became pain free and the hyperprolactinemia diminished. Fifteen months after his last cycle of temozolomide, his condition remains clinically stable and his serum prolactin levels are less than 50 ng/ml (Fig. 3) . He is asymptomatic and working full time. Follow-up MR images confirmed a partial response that has remained stable (Fig. 4) , and his visual fields are normal.
Discussion
Pituitary carcinoma is usually a lethal disease, with more than one half of patients dying within 1 year after a diagnosis. Long-term survivors have been reported, and perhaps the courses in the two described cases were the result of the natural history of the disease. Despite multiple treatment approaches, both of the patients had progressive disease, which was objectively determined based on prolactin concentration and PET scanning results in one case and on MR imaging studies and visual fields in the other. One of the patients underwent two cycles of systemic chemotherapy, which exacerbated his symptoms and produced no radiological evidence of a treatment response. Although there was some pain relief after MIBG treatment, prolactin levels did not decrease. Only after receiving temozolomide did the prolactin level decline 10-fold. There was no hormonal tumor marker to follow in the patient in the first case, but he had progressive visual impairment despite multiple treatments. Once he started taking temozolomide, his visual field deficits improved and the tumor decreased in size. In both cases the benefit lasted for more than 1 year after discontinuation of the therapy. Moreover, the drug was well tolerated except for fatigue.
In a review of chemotherapy for pituitary carcinoma, very few individuals showed an objective response to cytotoxic treatment. 5 Although exceptions have been reported, 1,10 the response has been transient and dependent on continuing chemotherapy. Despite having a high proliferation index, pituitary carcinomas usually do not respond to chemotherapy regimens known to be effective against adenocarcinomas or sarcomas, perhaps because pituitary carcinomas are well differentiated. Bromocriptine may produce some benefit in prolactin-producing tumors, but most of these lesions develop resistance to this drug. Tamoxifen has been suggested for use in this patient subgroup. 3 The persistence of a therapeutic response after discontinuing treatment is therefore a notable feature in the cases we describe.
Based on the outcome in these patients, who had not significantly responded to any other treatment, it seems plausible that these tumors were uniquely sensitive to temozolomide. This drug is an orally prescribed dacarbazine analog that crosses the blood-brain barrier. Furthermore, it has been shown to have activity against numerous malignancies, particularly intracerebral primary and metastatic tumors. 2, 14, 15 Cytotoxic activity against systemic adenocarcinomas, including pancreatic, renal cell, colorectal, and prostate carcinomas, has been disappointing. 4, 7, 8, 16 Results of an in vitro study of temozolomide for human tumors have suggested that this drug may have activity against neoplasms that did not respond to other agents such as dacarbazine, etoposide, and vinblastine. 12 In the patients in the present report, both the systemic and the craniospinal metastases responded to treatment, and this response was independent of whether or not the tumor was hormone secreting. Thus, we suggest that the location of the metastases and their hormone production status do not correlate with the response to temozolomide.
Although not ideal, treatment recommendations for rare tumors are often based on case reports. Given the lack of effective alternatives, a trial of temozolomide may be indicated before more toxic combinations of chemotherapy for the treatment of pituitary carcinoma. Only with more experience can we determine the response rates and durability of effectiveness associated with temozolomide treatment. If proven effective, this therapy could be studied in other patient subsets, such as those with invasive pituitary adenomas unresponsive to other treatments or with a high potential for aggressive behavior.
Addendum
Since this paper was submitted, the patient described in Case 2 FIG. 3. Case 2. Graph showing the serum prolactin concentration at approximately 6-month time intervals. The prolactin level was 694 ng/ml before starting temozolomide (TMZ) and decreased to 52 ng/ml after 10 treatment cycles. Prolactin levels remained below 50 ng/ml for more than 1 year after discontinuing chemotherapy. This patient continues to take highdose bromocriptine. had an increase in prolactin levels 15 months after temozolomide was discontinued. He exhibited no symptoms, but a PET scan revealed increased activity in the T-2 vertebral body as the only site of neoplastic activity. The patient has begun taking temozolomide again, but his prolactin levels have continued to increase.
